SynthesisAsian Pacific journal of cancer prevention : APJCP2026
Epstein-Barr Virus and Helicobacter pylori Co-Infection in Gastric Cancer: A Systematic Review and Meta-Analysis of Case-Control and Cross-Sectional Studies.
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is a multifactorial malignancy in which both Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV) have been implicated. Given the high prevalence of both pathogens, we performed a systematic review and meta-analysis to estimate the prevalence of H. pylori-EBV co-infection (HECo) in GC and to evaluate its association with GC.
methodsA systematic literature search was performed using a search strategy consisting of appropriate keywords in online databases including MEDLINE, Embase, and Web of Science from inception to July 2024. Eligible case-control and cross-sectional studies in English reported H. pylori and EBV status assessed using validated assays (e.g., PCR, serology, immunohistochemistry/in situ hybridization, rapid urease test), enabling ascertainment of HECo within the same participant. Study quality was assessed using the "Newcastle-Ottawa Quality Assessment Scale" (NOS) and the Appraisal Tool for Cross-Sectional Studies (AXIS tool). Random-effects meta-analyses were used to pool prevalence estimates and odds ratios (ORs) with 95% confidence intervals (CIs), and heterogeneity was quantified using I².
resultsEighteen studies (n = 4364; 1999-2023) were included. HECo prevalence among GC patients was 21.44% (95% CI: 9.46-33.42). HECo was associated with increased odds of GC (pooled OR = 3.09, 95% CI: 1.66-5.73; I² = 69.1%). Subgroup estimates by age (high vs low) were based on two studies per stratum and showed wide CIs (high age: OR = 9.61, 95% CI: 1.90-48.64; low age: OR = 9.52, 95% CI: 1.83-49.54) and should be interpreted cautiously. There was a significant association between the presence of metastasis, the high stage of GC, and HECo. Our results showed no significant association between moderately or poorly differentiated GC, diffuse-type GC, the presence of vessel invasion, and HECo.
conclusionHECo is associated with a higher risk of GC. Future primary studies should report mutually exclusive infection categories (HP only, EBV only, both, neither) and clarify the temporal relationship between infection and GC, to better disentangle independent versus joint effects and to inform prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.